Epidermal growth factor receptor (EGFR) protein overexpression is commonly found in human gastric cancer, and its gene amplification is known to correlate with poor prognosis in gastric cancer patients. With regard to therapy trials targeting EGFR, it has been reported that stable transfection of EGFR antisense or treatment with antibody against EGFR results in growth suppression of human cancer cells that express high levels of EGFR. We have designed an adenovirus-expressing antisense EGFR and have investigated its effect on the growth of gastric cancer in vitro and in vivo. Following infection with EGFR antisense RNA-expressing adenovirus (Ad-EAS), the cell surface EGFR protein levels of infected cancer cells were markedly reduced, and the in vitro growth of Ad-EAS-infected cells was significantly inhibited relative to control-infected cells in all three gastric cancer cell lines (AGS, KKLS, and MKN28) studied here (P Ͻ .0002). In a nude mouse subcutaneous tumor system, in vivo tumor growth of MKN28 was significantly inhibited after Ad-EAS treatment, and inhibition on day 48 was 93% by volume compared with that of untreated controls. These results suggest that an adenoviral vector system targeting the down-regulation of EGFR could be a good candidate for the therapy of gastric cancers that overexpress EGFR.
G
astric cancer is well known to have a very high incidence in eastern Asian countries, especially in Japan. Despite increased detection of early cancer, improved surgical techniques, and adjuvant therapies, the mortality associated with gastric cancer remains high due to carcinomatous peritonitis or distant metastasis in its advanced stages. 1, 2 Gene therapy in which a particular gene is transduced to control the growth and metastatic ability of cancer is considered to be a promising strategy in the treatment of advanced-stage gastric cancer.
Epidermal growth factor and its receptor (EGFR) have been reported to incite a series of events leading to cell proliferation; overexpression of EGFR leads to an aberrant activation of growth-signaling pathways that may result in neoplastic transformation. 3, 4 The EGFR gene is amplified and overexpressed in various kinds of human tumors, such as breast cancer, brain cancer, esophageal cancer, gastric cancer, and head and neck cancer. 4 Moroni et al 5 have reported that EGFR antisense RNA blocks expression of the EGFR and suppresses the transformed phenotype of a human carcinoma cell line; these investigators concluded that normal EGFR plays a direct primary role in the development of a human cancer cell line. Others have shown cancer cell growth inhibition using an antibody against EGFR 6, 7 or an EGFR antisense oligonucleotide 8 to block the EGFR-mediated growth signaling pathway.
In the present study, we have designed an adenoviral vector that expresses EGFR antisense RNA and examined its effects on the growth of three human gastric cancer cell lines both in vitro and in vivo.
MATERIALS AND METHODS

Cell culture
Three human gastric cancer cell lines (AGS, KKLS, and MKN28) and a human embryonal kidney cell line (293) were cultured in DMEM/F12 (Dulbecco's modified Eagle's medium, nutrient mixture F-12, and Ham 1:1) containing 10% fetal bovine sera at 37°C in a humidified atmosphere of 5% carbon dioxide and 95% air. AGS, MKN28, and 293 were obtained from the American Type Culture Collection (Manassas, Va) and KKLS was kindly provided by Dr. Takahashi (Kanazawa University, Cancer Research Institute, Kanazawa, Japan).
Preparation of adenovirus vectors
Preparation of recombinant antisense-EGFR adenovirus vector (Ad-EAS) was performed according to the method Graham and Prevec, 9 with some modifications. Briefly, a minigene cassette containing the 1.8-kilobase antisense-oriented human EGFR gene and simian virus 40 polyadenylation signal driven by a cytomegalovirus promoter was inserted into the E1-deleted region of modified adenovirus Ad5 that had been obtained from the digestion of adenovirus genome with ClaI and XbaI by homologous recombination. Monoclonal recombinant adenovirus was isolated from a single plaque, propagated in 293 cells (adenovirus E1a-transformed human embryonal kidney cells), and purified by CsCl-gradient ultracentrifugation. Concentrated virus solutions were stored at Ϫ80°C, and the viral titers were determined by modified endpoint cytopathic effect assay as described previously. 10 The adenovirus containing the Escherichia coli ␤-galactosidase (␤-gal) gene (Ad-␤-gal) driven by a cytomegalovirus promoter was used as a control.
Immunocytochemistry
A total of 5000 cells/well of MKN28 were seeded in an eight-chamber culture glass slide (Becton Dickinson Labware, Franklin Lakes, NJ); after 24 hours of incubation cells were infected with adenovirus at a multiplicity of infection (MOI) of 50. Two additional infections at the same MOI were performed over 2 days. Immunocytochemical staining for EGFR was performed 4 days after the initial infection. Sections were fixed with 4% paraformaldehyde and permeabilized with 100% methanol. Mouse anti-human EGFR monoclonal antibody (mAb) (Zymed Laboratories, San Francisco, Calif) was used for a primary antibody at a dilution of 1/30, and detection was done according to the streptavidin-biotin method using a Histofine SAB-PO(M) kit (Nichirei, Tokyo, Japan) and diaminobenzidine-tetrachloride (Sigma, Tokyo, Japan).
In vitro growth assay
Human gastric cancer cell lines were plated into a 96-well microtiter plate at a density of 2500 -5000 cells/well. As we reported previously, 11 a virus dose that exhibits satisfactory transduction without any cell toxicity was determined individually for each cell line by Ad-␤-gal transduction assay, resulting in an MOI of 50 for AGS, an MOI of 100 for KKLS, and an MOI of 150 for MKN28. After addition of the recombinant adenovirus (Ad-EAS or Ad-␤-gal) at the appropriate MOI, cells were harvested in final volume of 100 L of Dulbecco's modified Eagle's medium/F12 medium containing 1% fetal bovine sera. After 1-6 days of incubation, the cells were fixed with 5% glutaraldehyde and counted by the crystal violet staining procedure.
12
RNA preparation and dot blotting
For dot blotting, total RNA was extracted by Isogen (Nippon Gene, Tokyo, Japan) 24 hours after infection with adenovirus at an MOI of 50. A total of 5 g of collected total RNA was dot-blotted to a Hybond-N ϩ nylon membrane (Amersham, Arlington Heights, Ill) by the diluent method. Membranes were ultraviolet cross-linked by an autocross linker. A total of 50 ng of the 5Ј region of EGFR cRNA was labeled with [␣-32 P]dCTP (deoxycytidine triphosphate) using a Multiprime DNA labeling system (Amersham) as a probe, and hybridization was performed in a Rapid-hyb buffer (Amersham) at 65°C. The hybridized membrane was washed to the appropriate stringency with standard saline citrate solution containing 0.1% sodium dodecyl sulfate and exposed.
In vivo tumor treatment
To determine the effect of adenoviral vectors on tumor growth in vivo, the adenovirus was injected into nude mice. In brief, 5 ϫ 10 6 MKN28 cells suspended in 100 L of phosphatebuffered saline (PBS) were subcutaneously (s.c.) injected into the flanks of 5-week-old male BALB/c nude mice (Charles River, Kanagawa, Japan). Tumors were allowed to grow to a diameter of 4 -6 mm; next, either 100 L of Ad-EAS (10 9 plaque-forming units (PFU)), Ad-␤-gal (10 9 PFU), or PBS alone was injected directly into the tumor daily for 5 days using an insulin syringe with a 28-gauge needle. Five animals were used for Ad-␤-gal and PBS groups, and 10 animals were used for the Ad-EAS group. Tumor size was measured twice weekly; the tumor volume was calculated as follows: [length (mm) ϫ width (mm) 2 ]/2; tumor growth was evaluated by the relative tumor volume (RTV) according to the following formula: RTV ϭ TV n /TV 0 , where TV n is tumor volume at day n and TV 0 is tumor volume at day 0. The animals were sacrificed on day 48 after the initial injection of the adenovirus.
␤-gal staining
For ␤-gal staining, an animal was sacrificed 24 hours after a single injection of Ad-␤-gal (10 9 PFU), and the tumor was embedded in OCT (optimal cutting temperature) compound and frozen for thin sections. Frozen 10-m sections were cut using a cryostat, placed on polylysine-coated glass slides, air-dried, and stored at Ϫ20°C. Slides were fixed in 1.25% glutaraldehyde in PBS at 4°C for 10 minutes and rinsed twice with PBS containing 1 mM MgCl 2 at room temperature. ␤-gal staining was done for 3 hours at 37°C with X-Gal staining solution (1 mg/mL X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside), 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , and 1 mM MgCl 2 in PBS). The slide was removed from X-Gal solution, rinsed with PBS several times, mounted, and photographed.
Statistical analysis
Statistical analysis was performed by the Student t test throughout the present study.
RESULTS
Expression of EGFR antisense RNA and protein after Ad-EAS infection
To observe the expression of EGFR antisense RNA after Ad-EAS infection, dot blotting of total RNA was performed by the diluent method as described in Materials and Methods. EGFR antisense RNA was strongly expressed to a 1/100 dilution of RNA in Ad-EAS-treated cells but was not expressed in uninfected or Ad-␤-galinfected cells in all three cell lines (data not shown). Immunocytochemical analyses of MKN28 cells after Ad-EAS infection showed significant suppression of EGFR protein expression, whereas this suppression was not detected in noninfected or Ad-␤-gal-infected MKN28 cells (Fig 1, A-C) . This suppression of EGFR protein in Ad-EAS-treated cells was also confirmed by Western blotting that demonstrated a faint EGFR expression compared with noninfected cells.
Effect of Ad-EAS on growth of human gastric cancer cell lines in vitro
To determine whether Ad-EAS could inhibit tumor growth, we used three human gastric cancer cell lines, AGS, KKLS, and MKN28. Viral infections were performed at an MOI of 50 for AGS, an MOI of 100 for KKLS, and an MOI of 150 for MKN28, as described in Materials and Methods. The growth of the Ad-EASinfected cancer cells was significantly inhibited compared with noninfected or Ad-␤-gal-infected cancer cells in all three cell lines (Fig 2) . Although Ad-␤-gal showed slight growth inhibition, there was no significant difference between the Ad-␤-gal and noninfected groups. The growth inhibition of Ad-EAS-infected cells compared with noninfected cells on day 6 postinfection was 74.9% in AGS, 81.6% in KKLS, and 66.5% in MKN28, respectively (P Ͻ .0002).
Effect of Ad-EAS on growth of MKN28 cells in vivo
The exogenous gene transfer by adenovirus and the effect of Ad-EAS were studied in a tumor-bearing BALB/c nude mice system. At 24 hours after a single injection of Ad-␤-gal (10 9 PFU), exogenous gene transduction was confirmed by ␤-gal staining that exhibited blue-stained cells everywhere in the tumor (Fig 1D) . The effect of Ad-EAS on tumor growth in vivo was studied by an intratumoral injection of adenoviruses (10 9 PFU) daily for 5 days. After Ad-EAS treatment, the tumor showed no tendency to enlarge, and its growth was significantly inhibited. The growth inhibition of Ad-EAS-treated tumors on day 48 was 93% by volume compared with the PBS-or Ad-␤-gal-treated groups (Fig  3) . The Ad-␤-gal-treated tumors showed a slight growth inhibition in the early phase compared with the PBStreated group; however, the tumor doubling time was 8.6 days in the Ad-␤-gal group and 7.4 days in the PBS group, which were both significantly shorter than in the Ad-EAS-treated group. Throughout these experiments, there were no significant differences in body weight gain and no illness or accidental death of mice.
DISCUSSION
EGFR is a member of a tyrosine kinase family of cell surface receptors in which overexpression has been reported in many human malignancies, including brain cancer, head and neck cancer, breast cancer, lung cancer, and also gastric cancer. It has been reported that EGFR protein overexpression is commonly found in gastric cancer, and Hirono et al 4 have reported that the cumulative survival rate of gastric cancer patients with EGFR gene amplification was significantly lower than that of patients without amplification. Their results indicate that EGFR gene amplification in its advanced stages may play an important role in the progression of gastric cancer.
Therapy trials targeting EGFR and its ligand have been explored in several malignancies with EGFR overexpression. 6 -8,13,14 In an approach using a mAb against EGFR, Baselga et al 6 reported that anti-EGFR mAb enhanced the antitumor effect of doxorubicin against a breast cancer cell line, and Divgi et al 7 reported a clinical trial of anti-EGFR mAb in patients with squamous cell lung carcinoma. The efficacy of antisense therapies against EGFR for the treatment of human malignant disease is currently being evaluated. Moroni et al 5 have reported that the transformed phenotype of a human epidermoid carcinoma cell line was suppressed by microinjection of EGFR antisense RNA. With regard to an oligonucleotide approach against EGFR, growth inhibition by EGFR antisense oligonucleotide was reported in human head and neck cancer cells 8 and epidermoid carcinoma cells 13 in vitro. Rubenstein et al 14 have also reported the growth inhibitory effect of EGFR antisense oligonucleotide in human prostate cancer in vivo.
The goal of this antisense therapy is to block the expression of the targeted protein, ultimately inhibiting the downstream transcription pathways that are essential for cancer growth and progression. However, the clinical applicability of oligonucleotide or liposomal approaches seems to be limited, because of their relatively low efficiency of gene transduction, slow uptake into cells, and physiological instability. Among various vector systems that have been reported to date, the adenoviral vector seems to be a most clinically useful vector because of its simplicity in preparation and high efficiency of gene transduction regardless of tissue type and cell cycle. 15 Lee et al 16 reported the dramatic antitumor effects of antisense insulin-like growth factor receptor by intraperitoneal injection of adenoviral vector in nude mice bearing human lung cancer, indicating great promise for the adenoviral vector in in vivo antisense therapy. We have determined that adenoviral vectors are particularly suitable for our present study, which attempts to develop an effective gene therapy trial for the treatment of human gastric cancer. Previously, we have reported highly efficient gene transduction into gastric cancer cells by an adenoviral vector, 11 although there was a slight toxicity of Ad-␤-gal to cells that was most likely caused by virus toxicity itself and ␤-gal gene products. A nontoxic virus dose must be selected to analyze the effect of the virus-mediated gene transferred on each cell line, and the results should be evaluated in comparison with a group that received the same dose of control virus, such as Ad-␤-gal. In the present study, the dosage of 50 -200 MOIs for AGS, 100 -200 MOIs for KKLS, and 150 -500 MOIs for MKN28 was enough to achieve highly efficient gene transduction without cell toxicity.
We demonstrate gastric cancer growth inhibition by the suppression of EGFR protein levels via an antisense mRNA that was antisense to the 5Ј region of EGFR, including the initiation codon. We have confirmed EGFR expression by immunocytochemical analyses, Western blotting, and Northern blotting in all three cell lines (data not shown). By infecting cancer cells with Ad-EAS, a high expression of antisense RNA was observed; in addition, the expression of EGFR protein was significantly down-regulated in all three cell lines. During 6 days of observation, cancer cell growth was significantly inhibited by Ad-EAS infection in all three cell lines, whereas almost no growth inhibition was seen with Ad-␤-gal infection in any lines. Because the growth and EGFR expression of cancer cells was not affected by Ad-␤-gal, it is likely that this growth inhibition after Ad-EAS infection was brought about by a decreased expression of EGFR protein at the cell membrane. This anticancer growth mechanism via antisense EGFR was also effective in a xenografted tumor system in BALB/c nude mice. The s.c. tumor in the Ad-␤-gal group grew consistently; its average tumor doubling time was 8.6 days, which was not significantly different from that of the PBS group. Alternatively, the s.c. tumor in the Ad-EAS-treated group did not grow at all during the 48 days after the initial intratumoral virus injection. The Ad-EAS-treated s.c. tumors showed no tendency for regrowth and seemed to maintain a diameter of 2-6 mm (average, 3.14 mm) during the observation period after Ad-EAS treatment. However, microscopic analysis of S.C. tumors at the termination of the experiment did reveal some remaining viable cancer cells in the s.c. space. We have considered that this antisense-treated tumor will definitely regrow with further observation, and that this antisense therapy alone is unable to bring complete curability. In addition, further trials (perhaps a combination with chemotherapeutic agents) are necessary to achieve more effective inhibition. The virus dose we used for nude mice was 5 ϫ 10 9 PFU per single injection, and no critical side effect was observed in nude mice in any group. There was no significant difference in body weight among the three groups during the entire experiment.
Our results demonstrate that EGFR antisense, when delivered by an adenoviral vector, inhibits the growth of human gastric cancer cells in vitro and xenografted tumors in vivo. This finding suggests that an EGFRtargeting strategy could be a good candidate for cancer therapy in advanced gastric cancer patients and may deserve further evaluation for other types of cancers that show high EGFR protein expression.
